natgillin/translations-raw huggingface dataset:
Compared to the global phase III CRC trial (CORRECT) with predominantly (~80%) Caucasian patients enrolled, a higher incidence of liver enzyme increases was observed in Stivarga-treated patients in the Asian phase III CRC trial (CONCUR) with predominantly (> 90%) East Asian patients enrolled.
V primerjavi z globalnim preskušanjem III. faze (CORRECT) pri bolnikih z metastatskim kolorektalnim rakom, v katerega so bili vključeni pretežno belci (~ 80 %), so pri bolnikih, zdravljenih z zdravilom Stivarga, v preskušanjih pri bolnikih z metastatskim kolorektalnim rakom III. faze (CONCUR), v katerega so bili vključeni bolnikih azijske rase, pretežno (> 90 %) bolniki iz vzhodne Azije, opazili večjo incidenco povečanja vrednosti jetrnega encima.
Compared to the historical adult population receiving fosamprenavir / ritonavir 700 / 100 mg twice daily, 12 to 18 year old subjects had 20 % lower plasma APV AUC(0- 24), 23 % lower Cmax, and 20 % lower Cmin values.
V primerjavi s prejšnjo odraslo populacijo, ki je prejemala fosamprenavir/ritonavir 700/100 mg dvakrat na dan, so imeli od 12 do 18 let stari bolniki za 20 % nižje plazemske koncentracije APV (AUC(0-24)), za 23 % nižjo Cmax in 20 % nižje Cmin vrednosti.
Compared to the historical adult population receiving fosamprenavir with ritonavir 700 mg / 100 mg twice daily, a subset of five pediatric subjects ages 6 to < 24-months receiving fosamprenavir / ritonavir 45/7 mg/kg twice daily demonstrated that despite an approximate 5-fold increase in fosamprenavir and ritonavir doses on a mg/kg basis, plasma amprenavir AUC(0-) was approximately 48 % lower, Cmax 26 % lower, and C 29 % lower in the paediatric subjects.
Primerjava s prejšnjo odraslo populacijo, ki je prejemala fosamprenavir/ritonavir 700/100 mg dvakrat na dan, je pokazala, da je v podskupini bolnikov, starih od 6 od 24 mesecev, ki je dobivala fosamprenavir/ritonavir v odmerku 45/7 mg/kg na dan, kljub približno 5-kratnemu porastu odmerkov fosamprenavirja in ritonavirja, preračunano na kg telesne mase, pri pediatričnih bolnikih plazemska koncentracija amprenavirja pod krivuljo AUC (0-τ) padla za približno 48 %, Cmax je bila za 26 % nižja in Cτ za 29 % nižja.
Compared to the historical adult population receiving fosamprenavir with ritonavir 700 mg / 100 mg twice daily, a subset of five pediatric subjects ages 6 to < 24-months receiving fosamprenavir / ritonavir 45/7 mg/kg twice daily demonstrated that despite an approximate 5-fold increase in fosamprenavir and ritonavir doses on a mg/kg basis, plasma amprenavir AUC(0-) was approximately 48 % lower, Cmax 26 % lower, and C 29 % lower in the paediatric subjects.
Primerjava s prejšnjo odraslo populacijo, ki je prejemala fosamprenavir/ritonavir 700/100 mg dvakrat na dan, je pokazala, da je v podskupini bolnikov, starih od 6 od 24 mesecev, ki je dobivala fosamprenavir/ritonavir v odmerku 45/7 mg/kg na dan, kljub približno 5-kratnemu porastu odmerkov fosamprenavirja in ritonavirja, preračunano na kg telesne mase, pri pediatričnih bolnikih plazemska koncentracija amprenavirja pod krivuljo AUC(0-τ) padla za približno 48 %, Cmax je bila za 26 % nižja in Cτ za 29 % nižja.
Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and LUMIGAN 0.3 mg/mL (multi-dose formulation) lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg.
V primerjavi z zdravljenjem samo z antagonisti adrenenergičnih receptorjev beta, je adjuvantna terapija z antagonisti adrenenergičnih receptorjev beta in z zdravilom LUMIGAN 0,3 mg/ml (večodmerna oblika) zmanjšala povprečni jutranji (08:00) očesni tlak za –6,5 do –8,1 mmHg.
Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and LUMIGAN 0.3 mg/ml lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg.
V primerjavi z zdravljenjem samo z antagonisti adrenenergičnih receptorjev beta, je adjuvantna terapija z antagonisti adrenenergičnih receptorjev beta in z zdravilom LUMIGAN 0,3 mg/ml zmanjšala povprečni jutranji (08:00) očesni tlak za –6,5 do –8,1 mmHg.
Compared to voriconazole 200 mg
v primerjavi z vorikonazolom 200 mg BID,
Compared to voriconazole 200 mg BID,
v primerjavi z 200 mg vorikonazola BID,
Compared to voriconazole 200 mg BID,
v primerjavi z vorikonazolom 200 mg BID,
Compared to warfarin-treated subjects, the HR in the edoxaban 60 mg group was 0.87 (99% CI: 0.71, 1.07, p = 0.08 for superiority).
V primerjavi s preiskovanci, zdravljenimi z varfarinom, je bilo HR v skupini z edoksabanom 60 mg 0,87 (99 % CI: 0,71, 1,07, p = 0,08 za superiornost).
Compared with insulin glargine treatment, prolonged-release exenatide treatment significantly lowered mean body weight and was associated with fewer hypoglycaemic events (Table 3).
V primerjavi z insulinom glarginom je zdravljenje z eksenatidom v obliki s podaljšanim sproščanjem značilno znižalo srednjo vrednost telesne mase in je bilo povezano z redkejšimi hipoglikemičnimi dogodki (Preglednica 3).
Compared with patients who did not develop antibodies, no relationship between the presence of anti-panitumumab antibodies and pharmacokinetics, efficacy and safety has been observed.
V primerjavi z bolniki, pri katerih se protitelesa niso razvila, niso ugotovili povezanosti med prisotnostjo protiteles proti panitumumabu ter farmakokinetiko, učinkovitostjo in varnostjo.
Compared with patients with normal renal function, the mean (%CV) tenofovir exposure increased from 2,185 (12%) ng·h/ml in subjects with CrCl > 80 ml/min to respectively 3,064 (30%) ng·h/ml, 6,009 (42%) ng·h/ml and 15,985 (45%) ng·h/ml in patients with mild, moderate and severe renal impairment.
V primerjavi z bolniki z normalno ledvično funkcijo (CLCR > 80 ml/min) z srednjo vrednostjo (% koeficienta variacije) izpostavljenosti tenofovirju 2.185 (12%) ng·h/ml se je le-ta pri bolnikih z blago ledvično okvaro zvečala na 3.064 (30%) ng·h/ml, pri bolnikih z zmernimi motnjami na 6.009 (42%) ng·h/ml in na 15.985 (45%) ng·h/ml pri bolnikih z resnimi motnjami v delovanju ledvic.
Compared with placebo treatment, Thelin resulted in statistically significant improvement in pulmonary vascular resistance (PVR) and cardiac index (CI) after 12 weeks of treatment (see below).
V primerjavi s placebom je zdravljenje z zdravilom Thelin po 12 tednih statistično pomembno izboljšalo pljučno vaskularno odpornost (PVR – pulmonary vascular resistance) in srčni indeks (CI – cardiac index) (glejte spodaj).
Compared with placebo, fluticasone furoate nasal spray 110 micrograms once daily significantly improved nasal symptoms (comprising rhinorrhoea, nasal congestion, sneezing and nasal itching) and ocular symptoms (comprising itching/burning, tearing/watering and redness of the eyes) in all 4 studies.
V primerjavi s placebom je flutikazonfuroat v obliki pršila za nos v odmerku 110 mikrogramov enkrat na dan v vseh 4 študijah pomembno izboljšal nosne simptome (ki so obsegali nosni izcedek, kongestijo nosne sluznice, kihanje in srbenje nosu) in očesne simptome (ki so obsegali srbenje/pekoč občutek v očeh, solzenje/izcedek iz oči in rdečino oči).
Compared with placebo, there was a significant difference in favour of Xofigo for all five serum biomarkers for bone turnover studied in a phase II randomised study (bone formation markers: bone alkaline phosphatase [ALP], total ALP and procollagen I N propeptide [PINP], bone resorption markers: C-terminal crosslinking telopeptide of type I collagen [S-CTX-I] and type I collagen crosslinked C-telopeptide [ICTP]).
V randomizirani študiji II. faze so v primerjavi s placebom opazili pomembno razliko v korist zdravila Xofigo za vseh pet serumskih biokemičnih označevalcev kostne presnove (označevalci nastajanja kosti: kostna alkalna fosfataza [ALP], celokupna ALP in prokolagen I N propeptid [PINP], označevalci resorpcije kosti: C-terminalni prečno povezani telopeptid kolagena tipa I [S-CTX-I] in prečno povezani C-telopeptid kolagena tipa I [ICTP]).
Compared with placebo, ZOSTAVAX induced a higher VZV-specific immune response at 6 weeks postvaccination.
V primerjavi s placebom je bil s cepivom ZOSTAVAX 6 tednov po cepljenju dosežen večji imunski odziv, specifičen za VZV.
Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in Evista patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % Evista and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for Evista and 7.1 % placebo).
V primerjavi z bolnicami, ki so prejemale placebo, je bila pogostnost pojavov vazodilatacije (navali vročine) zmerno povečana pri bolnicah, zdravljenih z zdravilom Evista (pri kliničnih preskušanjih za preventivo osteoporoze, trajanje menopavze 2 do 8 let – 24,3 % pri zdravilu Evista in 18,2 % pri placebu; pri kliničnih raziskavah za zdravljenje osteoporoze, povprečna starost 66 let – 10,6 % pri zdravilu Evista in 7,1 % pri placebu).
Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in Optruma patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % Optruma and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for Optruma and 7.1 % placebo).
V primerjavi z bolnicami, ki so prejemale placebo, je bila pogostnost pojavov vazodilatacije (navali vročine) zmerno povečana pri bolnicah, zdravljenih z zdravilom Optruma (pri kliničnih preskušanjih za preventivo osteoporoze, trajanje menopavze 2 do 8 let – 24,3 % pri zdravilu Optruma in 18,2 % pri placebu; pri kliničnih raziskavah za zdravljenje osteoporoze, povprečna starost 66 let – 10,6 % pri zdravilu Optruma in 7,1 % pri placebu).
Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in raloxifene patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % raloxifene and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for raloxifene and 7.1 % placebo).
V primerjavi z bolnicami, ki so prejemale placebo, je bila pogostnost pojavov vazodilatacije (vročinskih oblivov) zmerno povečana pri bolnicah, zdravljenih z raloksifenom (pri kliničnih preskušanjih za preventivo osteoporoze, trajanje menopavze 2 do 8 let – 24,3 % pri raloksifenu in 18,2 % pri placebu; pri kliničnih raziskavah za zdravljenje osteoporoze, povprečna starost 66 let – 10,6 % pri raloksifenu in 7,1 % pri placebu).
Compared with positive controls (including phenobarbital, rifampicin), perampanel was found to weakly induce CYP2B6 (30 µmol/l) and CYP3A4/5 (≥3 µmol/l) among major hepatic CYPs and UGTs in cultured human hepatocytes.
Ugotovili so, da je v primerjavi s pozitivnimi kontrolami (vključno s fenobarbitalom, rifampicinom) perampanel šibek induktor CYP2B6 (30 µmol/l) in CYP3A4/5 (≥3 µmol/l) med pomembnejšimi jetrnimi encimi CYP in UGT v gojenih človeških hepatocitih.
Compared with published data for similar regimens without pertuzumab, high pCR rates were observed in all 3 treatment arms (see Table 3).
V primerjavi z objavljenimi podatki za podobne režime brez pertuzumaba so bili visoki deleži pCR opaženi v vseh treh zdravljenih skupinah (glejte Preglednico 3).
Compared with rituximab + placebo, treatment with idelalisib + rituximab resulted in statistically significant and clinically meaningful improvements in physical well-being, social well-being, functional well-being, as well as in the leukaemia-specific subscales of the Functional Assessment of Cancer Therapy: Leukaemia (FACT-LEU) instruments, and in statistically significant and clinically meaningful improvements in anxiety, depression and usual activities as measured by the EuroQoL Five-Dimensions (EQ-5D) instrument.
V primerjavi z rituksimabom + placebom je zdravljenje z idelalizibom + rituksimabom povzročilo statistično značilna in klinično pomembna izboljšanja fizičnega dobrega počutja, socialnega dobrega počutja, funkcionalnega dobrega počutja in podlestvic orodij za funkcionalno oceno zdravljenja raka, specifičnih za levkemijo (FACT-LEU, Functional Assessment of Cancer Therapy: Leukaemia), in statistično značilna in klinično pomembna izboljšanja tesnobnosti, potrtosti in običajnih dejavnosti, izmerjeno s petdimenzionalnim orodjem EuroQoL (EQ-5D).
Compared with younger subjects (<65), more subjects ≥65 years old had adverse reactions that led to study drug dose modifications (interruptions or reductions) (23% versus 17%).
V primerjavi z mlajšimi bolniki (< 65 let) je imelo več bolnikov v starosti ≥ 65 let neželene učinke, ki so zahtevali prilagoditve odmerka raziskovanega zdravila (prekinitve ali zmanjšanja) (23 % v primerjavi s 17 %).
Comparison based on historical control
Primerjava temelji na zgodovinskih kontrolnih podatkih
Comparison between PD-L1 IHC staining in archival tissue vs newly obtained (melanoma studies only)
Primerjava med barvanjem po IHC metodi za PD-L1 v arhiviranem tkivu in na novo pridobljenem tkivu (samo študije melanoma)
Comparison between the survival curves of the two treatment arms using the log rank test showed a statistically significant difference between the curves of the two groups in the ITT population (p=0.0014) indicating a significant delay in the progression to cancer.‌
Primerjava med krivuljama preživetja pri dveh zdravljenih skupinah z uporabo testa log rank je pokazala statistično pomembno razliko med krivuljama v obeh skupinah populacije ITT (p=0,0014), kar kaže na pomemben zastoj v napredovanju raka.
Comparison of 218 patients with mild renal impairment at baseline (CrCl 51 to 80 ml/min) to 297 patients with normal renal function at baseline (CrCl >80 ml/min) treated with Teysuno in combination with cisplatin in the FLAGS study indicated that there were no clinically significant differences in safety between patients with mild renal impairment and patients with normal renal function.
Primerjava 218 bolnikov z blago izhodiščno ledvično okvaro (CrCl 51–80 ml/min) in 297 bolnikov z normalno izhodiščno ledvično funkcijo (CrCl > 80 ml/min), zdravljenih z zdravilom Teysuno v kombinaciji s cisplatinom, v študiji FLAGS je pokazala, da med bolniki z blago ledvično okvaro in bolniki z normalno ledvično funkcijo ni bilo klinično pomembnih razlik glede varnosti.
Comparison of Gardasil 9 with qHPV vaccine with respect to HPV types 6, 11, 16, and 18 were conducted in a population of 16- through 26-year-old women from Protocol 001, 9- through 15-year- old girls from GDS01C/Protocol 009 and 16- through 26-year-old men from GDS07C/Protocol 020.
Primerjavo cepiva Gardasil 9 in qHPV cepiva glede tipov HPV 6, 11, 16 in 18 so izvedli v populaciji žensk, starih od 16 do 26 let, iz Protokola 001, populaciji deklic, starih od 9 do 15 let, iz GDS01C/Protokola 009 in populaciji moških, starih od 16 do 26 let, iz GDS07C/Protokola 020.
Comparison of Mean Diurnal IOP (mmHg) Change from Baseline– Non-inferiority Study
Primerjava srednje spremembe vrednosti očesnega tlaka čez dan (mmHg) glede na začetne vednosti – študija neinferiornosti
Comparison of PD-L1 IHC between pre and post treatment tumour tissues (melanoma studies only)
Primerjava med barvanjem po IHC metodi za PD-L1 v tumorskem tkivu pred in po zdravljenju (samo študije melanoma)
Comparison of Pharmacokinetic Parameters of IDELVION by Age Category (Median (min, max)) Following a Single Injection of 50 IU/kg IDELVION
Primerjava farmakokinetičnih parametrov zdravila IDELVION po starostnih skupinah (mediana (min, maks)) po enkratni injekciji zdravila IDELVION v odmerku 50 i.e./kg
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study (H0648g) in which patients were treated concomitantly with Herceptin and paclitaxel and two Phase II studies in which Herceptin was administered as monotherapy (W016229 and MO16982), in women with HER2-positive MBC indicates that individual and mean trastuzumab trough serum concentrations varied within and across studies but there was no clear effect of the concomitant administration of paclitaxel on the pharmacokinetics of trastuzumab.
Primerjava farmakokinetičnih rezultatov iz dveh študij faze II (BO15935 in M77004) in ene študije faze III (HO648g), v kateri so bolnike sočasno zdravili z zdravilom Herceptin in paklitakselom, ter dveh študij faze II, v katerih so dajali Herceptin v monoterapiji (WO16229 in MO16982) bolnicam s HER2-pozitivnim metastatskim rakom dojk, nakazuje, da so se posamezne in povprečne najnižje serumske koncentracije trastuzumaba razlikovaleo znotraj študij in med njimi, jasnega vpliva sočasne aplikacije paklitaksela na farmakokinetiko trastuzumaba pa ni bilo.
Comparison of the images obtained with Rapiscan to those obtained with adenosine was performed as follows.
Primerjava posnetkov, pridobljenih z uporabo zdravila Rapiscan, s tistimi, pri katerih je bil uporabljen adenozin, je bila opravljena na naslednji način.
Comparison to exposure in
Primerjava izpostavljenosti pri
Comparison vs placebo
Primerjava s placebom
Comparison vs placebo1
Primerjava s placebom1
Comparison vs. empa (95% CI)1
Primerjava z empa (95 % IZ)1
Comparison vs. met (95% CI)1
Primerjava z met (95 % IZ)1
Comparison with intravenous data indicated an average bioavailability of about 50% at the recommended dose level of 1.0 mg/kg/wk subcutaneous.
Primerjava z intravenskimi podatki kaže, da je povprečna biološka uporabnost priporočenega subkutanega odmerka 1,0 mg/kg/teden enaka 50 %.
Compartment for needles
razdelek za igle
Compartment syndrome has been reported as a complication of forearm haematoma following administration of bivalirudin via the radial access route in post-marketing experience
O utesnitvenem sindromu so poročali kot o komplikaciji hematoma podlakti, do katere je prišlo po aplikaciji bivalirudina po radialni poti v okviru izkušenj v obdobju trženja
Compartment syndrome secondary to a bleeding
utesnitveni sindrom sekundarno po krvavitvi
Compartment syndrome secondary to a bleeding
utesnitveni sindrom, sekundarno po krvavitvi
Compartment syndromea, b
utesnitveni sindroma, b
Compatibility of Vistide with Ringer’s Solution, Lactated Ringer’s Solution or bacteriostatic infusion fluids has not been evaluated.
Združljivost zdravila Vistide z Ringerjevo raztopino, Ringerjevo laktatno raztopino in bakteriostatskimi infuzijskimi tekočinami ni raziskana.
Compatibility studies have demonstrated glycerol phenylbutyrate chemical and physical in-use stability with the following foods and nutritional supplements: apple sauce, ketchup, squash, and five medical formulas (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree and Citrulline) typically consumed by UCD patients (see section 4.2).
Študije o združljivosti so pokazale kemično in fizično stabilnost glicerol fenilbutirata z naslednjimi živili in prehranskimi dopolnili: jabolčna čežana, paradižnikov kečap, buča in pet medicinskih pripravkov (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree in Citrulline), ki jih običajno uživajo bolniki z UCD (glejte poglavje 4.2).
Compatibility with ear cleaners, other than saline, has not been demonstrated.
Združljivost s čistili za ušesa, razen s fiziološko raztopino, ni bila dokazana.
Compatibility with Ringer’s Solution, Lactated Ringer’s Solution or bacteriostatic infusion fluids has not been evaluated.
Združljivost z Ringerjevo raztopino, Ringerjevo laktatno raztopino ali bakteriostatskimi infuzijskimi tekočinami ni raziskana.
Compatibility with the following infusion sets has been verified:
Preverili so združljivost z naslednjimi infuzijskimi kompleti:
Compatible concentrations
Združljive koncentracije
Compatible Infusion Solutions:
Združljive raztopine za infundiranje:
Compatible intravenous solutions include: sodium chloride 9 mg/ml (0.9 %) solution for injection, dextrose 50 mg/ml (5 %) solution for injection, and Lactated Ringer’s solution for injection.
Med kompatibilnimi intravenskimi raztopinami so 0,9-odstotna (9 mg/ml) raztopina natrijevega klorida za injiciranje, 5-odstotna (50 mg/ml) raztopina glukoze za injiciranje in raztopina Ringerjevega laktata za injiciranje.
compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1).
s kompenzirano jetrno boleznijo in dokazano aktivno imunsko boleznijo, tj. aktivno replikacijo virusov, persistentno zvišano vrednostjo ALT v serumu ter histološko dokazanim aktivnim vnetjem in/ali fibrozo (glejte poglavja 4.4, 4.8 in 5.1).
Compensated liver disease is when the liver is damaged but is still able to work normally.
Kompenzirana bolezen jeter pomeni, da so jetra poškodovana, vendar še vedno lahko normalno delujejo.
compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis.
kompenzirano boleznijo jeter z dokazom aktivne virusne replikacije, z vztrajno povišano vrednostjo serumske alanin-aminotransferaze (ALT) in histološkim dokazom aktivnega vnetja jeter in fibroze.
compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis.
s kompenzirano jetrno boleznijo, z dokazano aktivno replikacijo virusa, s trajnim povečanjem vrednosti serumske alanin-aminotransferaze (ALT) in histološkimi dokazi aktivnega vnetja in/ali fibroze jeter.
compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis.
s kompenzirano jetrno boleznijo, z znaki aktivne replikacije virusa, s trajnim povečanjem vrednosti serumske alanin-aminotransferaze (ALT) in histološkimi dokazi aktivnega vnetja in/ali fibroze jeter.
Competact
Zdravilo Competact
Competact has no or negligible influence on the ability to drive and use machines.
Zdravilo Competact nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Competact is contraindicated in patients with:
Zdravilo Competact je kontraindicirano pri:
Competact is not recommended in women of childbearing potential not using contraception.
Zdravilo Competact ni priporočljivo pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Competact should not be used in patients with renal failure or renal dysfunction (creatinine clearance< 60 ml/min) (see sections 4.3 and 4.4).
Zdravilo Competact se ne sme uporabljati pri bolnikih z ledvično odpovedjo ali ledvično disfunkcijo (očistek kreatinina < 60 ml/min) (glejte poglavji 4.3 in 4.4).
Compilation of clinical and laboratory data
Klinični in laboratorijski podatki skupaj.
Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.
O pritožbah zaradi reakcij na mestu injiciranja (bolečina na mestu injiciranja, reakcija na mestu injiciranja) in kožnih reakcij (izpuščaj, urtikarija) so poročali relativno bolj pogosto pri otrocih in mladostnikih, starih 18 let ali manj, kot pri odraslih.
Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.
O pritožbah zaradi reakcij na mestu injiciranja (bolečine na mestu injiciranja, reakcija na mestu injiciranja) in kožnih reakcij (izpuščaj, urtikarija) so poročali relativno bolj pogosto pri otrocih in bolnikih, starih 18 let ali manj, kot pri odraslih.
Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.
O pritožbah zaradi reakcij na mestu injiciranja in kožnih reakcij so poročali relativno bolj pogosto pri bolnikih, starih 18 let ali manj, kot pri odraslih bolnikih.